NEWS
NousCom receives $49M to trial off-the-shelf cancer vaccine
Cancer vaccine startup NousCom has raised €42 million ($49…
AstraZeneca bolts Incyte’s IDO1 immunomodulator to its lung cancer plans
AstraZeneca has enlisted the aid of Incyte to try to boost its…
Incyte pays MacroGenics $150M for PD-1 inhibitor
Incyte is paying $150 million upfront for worldwide rights to…
Gilead buys CAR-T developer Kite Pharma for $12B
Gilead Sciences CEO John Milligan, under pressure from a flagging…
Bone marrow cancer and immuno-oncology research agreement
Australian immuno-oncology company HaemaLogiX has signed an agreement…
Servier, Pieris launch up to $1.8B immuno-oncology alliance
Servier will partner with Pieris Pharmaceuticals to co-develop…
Roche bets up to $1B on Blueprint’s immunomodulation platform
Roche is promising up to $1 billion in exchange for as many as…
Lilly signs a $1B deal to deepen its oncology ties with China’s Innovent
Eli Lilly ($LLY) has expanded its R&D partnership with China's…
Novartis inks a string of deals to widen its immuno-oncology arsenal
Novartis ($NVS), developing cancer treatments that tap the power…
Moderna joins the personalized cancer vaccine rush with third new venture
Moderna Therapeutics is launching the third new personalized…
Cancer Vaccines Market Growing at 27% CAGR to 2019
The Global Cancer Vaccines Market 2015-2019 report says use of…
Soon-Shiong’s NantCell hauls in another $100M for immuno-oncology R&D
NantCell, one of billionaire entrepreneur Patrick Soon-Shiong's…